RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:585918

B-lymphoblastic leukemia/lymphoma with t(v;11q23.3)

high confidenceSubtype of disorder

Also known as: B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged · B lymphoblastic leukemia lymphoma with t(v;11q23); MLL rearranged

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

12

24.9th percentile

Trials

0

Interventional, condition-specific

Researchers

84

Distinct authors in sample

Gene link

—

Readiness

1/6

Stages with a signal

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (1)

B lymphoblastic leukaemia lymphoma with t(v;11q23); MLL rearranged

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

1/6 stages with a signal

Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    12 matched papers (8 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

12

12 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

12 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

8 in the last 10 years · high confidence · 24.9th percentile (publications denominator)

Phrase hits: 12 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

84

Distinct author names in 12 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Ahmad T1 paper · 2026

    Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

    Papers in Europe PMC
  2. 02
    Aplan PD1 paper · 2009
    Papers in Europe PMC
  3. 03
    August KJ1 paper · 2026

    Departments of Pathology and Pediatrics, University of Missouri Kansas City - School of Medicine, Kansas City, MO, USA.

    Papers in Europe PMC
  4. 04
    Aureli A1 paper · 2023

    CNR Institute of Translational Pharmacology, Via Carducci 32, 67100 L'Aquila, Italy.

    Papers in Europe PMC
  5. 05
    Azzarà A1 paper · 2012
    Papers in Europe PMC
  6. 06
    Bataller A1 paper · 2021

    Josep Carreras Leukemia Research Institute, Campus Clinic, School of Medicine, University of Barcelona, 08036 Barcelona, Spain.

    Papers in Europe PMC
  7. 07
    Bi C1 paper · 2026

    Departments of Pathology and Pediatrics, University of Missouri Kansas City - School of Medicine, Kansas City, MO, USA.

    Papers in Europe PMC
  8. 08
    Brunner AM1 paper · 2020

    Massachusetts General Hospital, Zero Emerson Place Suite 118, Boston, MA, 02114, USA. abrunner@mgh.harvard.edu.

    Papers in Europe PMC
  9. 09
    Bryant A1 paper · 2026

    Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

    Papers in Europe PMC
  10. 10
    Budzyńska J1 paper · 2023

    Student Scientific Society of the Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

high confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"B-lymphoblastic leukemia/lymphoma with t(v;11q23.3)" OR "B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged" OR "B lymphoblastic leukemia lymphoma with t(v;11q23); MLL rearranged" OR "B lymphoblastic leukaemia lymphoma with t(v;11q23); MLL rearranged"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"B-lymphoblastic leukemia/lymphoma with t(v;11q23.3)" OR "B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged" OR "B lymphoblastic leukemia lymphoma with t(v;11q23); MLL rearranged" OR "B lymphoblastic leukaemia lymphoma with t(v;11q23); MLL rearranged" OR "B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality" OR "precursor lymphoblastic lymphoma/leukemia"

Recall-expansion terms: B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality, precursor lymphoblastic lymphoma/leukemia

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T18:44:01.080Z